• infusion
  • This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA. (bioportfolio.com)
  • outcome
  • Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? (harvard.edu)